Neogenomics Stock Earnings Reports

NeoGenomics reported strong Q1 2026 performance, with total revenue of $186.7M (+11% YoY) and clinical revenue of $171.2M (+14% YoY). NGS remains the primary growth driver (NGS revenue +26% YoY) and now represents roughly one-third of clinical revenue. The company launched RaDaR ST (high-sensitivity MRD) and received MolDX reimbursement for PanTracer Liquid Biopsy, both cited as large addressable-market catalysts. Adjusted EBITDA was $9M (+27% YoY) with margin expansion of ~60 bps; adjusted gross margin declined modestly in Q1 due to Pathline acquisition dilution, an early PanTracer Liquid launch prior to MolDX approval, and higher freight/fuel costs, but management expects ~100 bps of full-year gross margin expansion driven by lab automation and other efficiency initiatives. Management increased full-year 2026 revenue guidance to $797M–$803M (midpoint up vs. prior) while reiterating adjusted EBITDA guidance of $55M–$57M. Key commercial priorities include expanding the sales force (~25 added reps by Q3), accelerating Epic Aura integrations to drive adoption, and pursuing two additional MolDX submissions for RaDaR ST that could materially expand the MRD market opportunity later in the year. Nonclinical/pharma revenue was down (~15% YoY) and is expected to remain pressured in the near term, with improvement anticipated in H2. Cash position was $146M at quarter end; management plans to refinance a $342M convertible due Jan 2028 in H2. Overall, the company emphasizes sustainable, above-market NGS growth, commercialization of high-value products (PanTracer family, RaDaR ST), and margin uplift from operational investments.